202 results about "Sensitive cell" patented technology

This invention relates to single session image guided all field simultaneous radiation therapy combined with hyperthermia. Hyperthermia renders the radiation resistant cells as more radiation sensitive cells. The high and super-high dose rate radiation greatly improves the RBE of the photon radiation. It also minimizes photon radiation therapy's OER and cell cycle dependent tumor cell kill by minimizing the repair capacity of cell after photon radiation. Single session hyperthermia and radiation therapy overcomes the thermotolerance-associated inefficiency of hyperthermia treatment as it is when hyperthermia is combined with fractionated, lower dose rate radiation. The synergetic effects of sublethal damage repair inhibiting single session hyperthermia-combined with high dose and dose rate single session radiation therapy, and combined chemotherapy brings the photon radiation therapy's tumor cure and control capabilities closer to high LET radiation therapy.

A method of utilizing the physiological activity of a rare saccharide, wherein physiological-activity sensitive cells are treated with the rare saccharide to modify the function of the cells. A composition containing, as an active ingredient, a rare saccharide which is introduced into physiological-activity sensitive cells and has an effect of modifying the function of the cells. The cells are human cells. The composition is a functional food, a drug, or a cosmetic. The rare saccharide is a rare saccharide belonging to aldose and/or ketose. The aldose is D-allose, and the cells are selected from the group consisting of cancer-cell proliferation inhibitory activity sensitive cells and active-oxygen production inhibitory activity sensitive cells. The ketose is D-psicose, and the cells are selected from the group consisting of chemokine secretion inhibitory activity sensitive cells, microglia migration inhibitory activity sensitive cells, and hypoglycemic activity sensitive cells.

A solid-state image sensor includes photo-sensitive cells arranged in a bidimensional array for converting incident light to corresponding signal charges. Vertical transfer paths transfer the signal charges read out from the photo-sensitive cells in the vertical direction. The photo-sensitive cells are made up of first and second photo-sensitive cells each having particular sensitivity to incident light. The first and second photo-sensitive cells are positioned at one diagonal corners and the other diagonal corners, respectively, at opposite sides of each vertical transfer path such that the first and second photo-sensitive cells have photo-sensitive areas whose centers of gravity form a rectangle when connected by a virtual line.

The invention belongs to the field of biotechnology, and relates to a slightly acidic environment targeted polypeptide modified tumor targeted nano drug delivery system, and a preparation method thereof. The slightly acidic environment targeted polypeptide modified tumor targeted nano drug delivery system is prepared via self-assembly of a slightly acidic environment targeted polypeptide modified dendrimer encapsulated gene, wherein the surface of the dendrimer is rich of amino groups. According to the preparation method, a polypeptide of transmembrane helix protein C derived from bacteria visual purple is used for modifying a high molecular carrier, enrichment and adhesion onto cells is realized via a pH sensitive cell membrane insertion method, and entering into cells is realized via electrostatic adsorption guided endocytosis, so that untaking of tumor cells on drugs is improved, and toxic and side effects are reduced. According to the tumor targeted nano drug delivery system, cell membrane is taken as the target point, and the polypeptide is taken as the target head group in tumor slightly acidic environment, targeting and curing efficiency are high, the preparation method is simple and convenient, and tumor cell drugs, which are derived from human or animal, and is used for targeted therapy, can be prepared.

PURPOSE: Provided are a method and a substance useful for treatment and diagnosis of prostate cancer. Particularly, provided are a peptide having a specific sequence, a mutant thereof and a nucleic acid encoding the same. CONSTITUTION: An HLA-A24- restricted antigen peptide is characterized by being capable of inducing a CTL(cytotoxic lymphocyte) having a T cell receptor specifically recognizing a cell manifesting on the cell surface a complex between the peptide and HLA(human main histocompatibility antigen)-A24 molecule.

A device for measuring the position of at least one moving object in a three-dimensional grid. The device comprises: at least one optical head comprising an independent laser sources array outputting collimated laser beams, arranged about a central photodetector with a single sensitive cell; at least one movable base with two rotational degrees of freedom whereto said array is secured; and control electronics.

A composite comprising a stem cell; a biodegradable layer, which can provide an environment for the stem cell to grow and to differentiate, and; a N-isopropylacrylamide (NIPAAm), which can polymerize with the biodegradable layer and possess the temperature-responsive character for easy stripping. This invention also provides a method of treating a subject with a skin defect by covering the composite of the present invention on the skin defect of the subject in need of such treatment. Furthermore, using this composite with different growth factors, stem cells can be induced to differentiate into skin-related, neuronal cells, neuron, and insulin-positive cells in biodegradable scaffolds as well as transplanted graft. Finally, this invention also provides a quick and convenient method of monitoring cell growth or tissue engineering in an animal.

The invention relates to the field of biotechnology, and particularly relates to a method for performing screening in virus-sensitive cell clonal strains by applying an indirect immunofluorescence assay technology. The method comprises the following steps of: identifying the purity of a cell line; obtaining monoclonal cell strains in the cell line; and identifying the sensitivity of the monoclonal cell strains to virus. The method disclosed by the invention has the beneficial effects of being short in detection time, capable of identifying the sensitivity of single-cell cloning to virus only by 3 days, relative simple to operate, easy, capable of being used for screening lots of non-cytopathic virus-sensitive cell strains, stable in result, strong in repeatability, and consistent with the effect of a virulence determination method.

The instant invention employs an array of rods packed into a suitable chamber to support the culture, e.g., maintenance and/or growth of anchorage-dependent cells that effectively increases the surface area available for cell culture. Adherent cells are seeded and propagated on the surface of the rods. Each rod is accommodated with spacer devices that serve to make it immobile and ensure uniform access to liquid growth medium while minimizing abrasive damage to shear-sensitive cells. Spacer devices of various designs allow the rods to be packed and anchored into bioreactors, e.g., perfusion chambers with flow-through ports or into closed roller bottle-type chambers. Simple monomeric designs of the rods and spacer devices allow for relative ease of manufacture and assembly including solid or hollow rods or supports constructed of fibers or strings consisting of flexible tissue culture treated material that is held fast by threading or knotting between suitable spacer devices with eyelets, holes or other anchoring fixtures. In some embodiments, the rods are composed of tissue culture-treated plastic packed into culture chambers as prepackaged, sterile, disposable single use items.

The invention discloses a humanized anti-novel coronavirus neutralizing antibody nCoV-61 and an application thereof. The humanized neutralizing antibody nCoV-61 specific to the novel coronavirus surface antigen is successfully obtained by utilizing a phage antibody library technology, has a neutralizing function of preventing the novel coronavirus from infecting sensitive cells in vitro, and is high in antigen affinity, and the antibody is expected to be prepared into specific antibody drugs for preventing and treating novel coronavirus pneumonia clinically.

The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof:

[where R¹ represents hydrogen atom or lower alkoxy group; R² represents hydrogen atom, lower alkoxy group, optionally substituted phenyl group,

(where R³ represents acyl group); X represents —CO— or —CH₂—; and n-represents 1 or 2], as drugs for overcoming a resistance to anticancer drugs or drugs for enhancing an effect of anticancer drugs. The compounds represented by the general formula [1] have not only a function of overcoming the resistance to various anticancer drugs but also a function of enhancing the effect of various anticancer drugs to anticancer-drug sensitive cells. Thus, these compounds have excellent effects on resistant cells and also on sensitive cells, and in particular effective in the treatment of a cancer having an acquired resistance to an anticancer drug.

The invention discloses a humanized anti-novel coronavirus neutralizing antibody nCoV-121 and application thereof. The humanized neutralizing antibody nCoV-121 specifically aiming at a novel coronavirus surface antigen is successfully obtained with a phage antibody library technology, has a neutralizing function of preventing the novel coronavirus from infecting sensitive cells in vitro and is high in antigen affinity, thereby being expected to be prepared into specific antibody drugs for preventing and treating novel coronavirus pneumonia clinically.

The invention discloses ribonucleic acid interference (RNAi) for inhibiting porcine reproductiion and respiratory syndrome virus (PRRSV) replication and a preparation method of RNAi, The RNAi comprises a small interfering RNA (siRNA) sequence. The preparation method comprises the steps of constructing a short hairpin RNA (shRNA) slow virus expression vector, preparing replication-defective slow virus, infecting slow virus Marc-145 cells (green monkey kidney cells) and the like. The invention also discloses a method for verifying the effect of inhibiting PRRSV from replication. The RNAi sequence has the obvious effect of inhibiting the PRRSV replication on sensitive cells. According to the invention, the exploration of RNA interference on in vitro and vivo replication of hog cholera virus is carried out, a slow-virtue-mediated stably-integrated RNA interfering technology for special conserved gene segments of a targeted hog cholera virus genome is constructed, and transgenic animals with the siRNA of targeted hog PRRSV are hopeful to construct. The necessary experimental data is accumulated for gene function research of RNAi applied to PRRSV and prevention and treatment of hog cholera, and early-stage preparation is provided for disease resistance breeding of animals.

The invention provides a method for producing a blue-ear disease vaccine by culturing a sensitive cell. The method comprises the following steps: 1) culturing the sensitive cell on a microcarrier in a bioreactor; 2) inoculating a porcine reproductive and respiratory syndrome virus to the sensitive cell cultured on the microcarrier; 3) continuously culturing the sensitive cell; and 4) obtaining virus solution to produce the blue-ear disease vaccine. The method produces the blue-ear disease vaccine by culturing the sensitive cell in the bioreactor by applying microcarrier culture technology. The microcarrier provides larger surface area, the cell can reproduce to generate higher cell density, and automatically controlled culture environment parameters of the bioreactor ensure that the cell growth and virus propagation can be in an excellent environment, so the method can improve the virus titer, and ensures more stable vaccine quality.

A time delay integration (TDI) sensor (22) comprises a sequence of cells (42, 44, 42, 44) numbered 1 to N. The TDI sensor is configured for transferring a charge from the cell numbered 1 via the cells numbered 2 to N-1 to the cell numbered N. Each cell (42; 44) in the sequence of cells is either sensitive or insensitive in the sense that when the TDI sensor (22) is evenly illuminated by light (46) incident on any of the insensitive cells (44) is at most 90% of the intensity of the light (46) incident on any of the sensitive cells (42). The sequence of cells (42, 44, 42, 44) comprises, in this order: a first sensitive cell (42), at least one insensitive cell (44), and a second sensitive cell (42). An imaging system comprising a TDI sensor and a method of imaging an object are also disclosed.

The invention discloses a humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof. According to the humanized anti-novel coronavirus neutralizing antibody nCoV-163 andthe application thereof, the humanized neutralizing antibody nCoV-163 specifically aiming at a novel coronavirus surface antigen is successfully obtained by utilizing a phage antibody library technology, the antibody nCoV-163 is provided with a neutralizing function of preventing novel coronavirus from infecting sensitive cells in vitro and is high in antigen affinity, and the antibody is expectedto be prepared into specific antibody drugs for preventing and treating novel coronavirus pneumonia clinically.

The invention relates to the field of veterinary biological products and particularly relates to a preparation method of a mink canine distemper virus live vaccine. The method comprises the following steps: inoculating a bioreactor with sensitive cells for vaccine preparation, and culturing by using a micro-carrier; after the sensitive cells are cultured by over 50% and grow into a dense single layer, inoculating the bioreactor with canine distemper virus for enrichment culture; harvesting the virus culture liquid and micro-carrier; performing freeze-thawing and removing the micro-carrier and cell debris to obtain virus liquid; and blending the virus liquid to obtain the vaccine. By improving the reaction conditions of each step and optimizing the production flow, the method provided by the invention realizes the technical effects of short production cycle, high virus titer, stable product quality, increased production efficiency and low side effect.

The invention provides a method for suspension culture of sensitive cells, which comprises the following steps that: (1) expression vectors containing gene sequences, capable of weakening the cell adhesion performance, are used for stably transfecting Marc145 cells or MA104 cells; (2) a stable transfection cell clone is screened and separated; (3) the gene expression in the stable transfection cell clone is detected; and (4) the stable transfection cell clone is subjected to suspension culture. The method further relates to a method for producing blue ear disease vaccine vaccine by using the Marc145 cells or MA104 cells obtained through the suspension culture.

The invention provides a 2-(9-methylene anthracene) thiosemicarbazide and TAT modified gold nanoparticle drug delivery system. The 2-(9-methylene anthracene) thiosemicarbazide and TAT modified gold nanoparticle drug delivery system has the advantages that a gold nanosphere drug delivery system with the particle size being 3.8nm (sodium borohydride reduction method) and a gold nanosphere drug delivery system with the particle size being 22.1nm (sodium citrate reduction method) are built, the surfaces of the systems are modified with polypeptide TAT, the systems modified by the polypeptide TAT are used as the carriers of 2-(9-methylene anthracene) thiosemicarbazide, the fact that the drug-resistance index of large-particle-size gold nanospheres to drug-resistance cells is smaller is discovered through the antitumor activity evaluation of MCF-7 sensitive cells and MCF-7/ADR drug-resistance cells, and the fact shows that large-particle-size carriers are more suitable for tumor drug resistance treatment and the 22.1nm gold nanospheres have an enhancing effect on the Raman signal of the 2-(9-methylene anthracene) thiosemicarbazide and can be used for cellular-level Raman imaging.

The invention discloses a self-cloning new human tumor drug-resistant related gene, namely TCRP1, wherein the gene and drug resistance generation of tumor chemotherapy platinum drugs has confidential relation. The expression of TCRP1 in platinum secondary drug-resistant tumor cell strains such as Tca8113/PYM, A549/DDP, Coc1/DDP is raised, and the expression of TCRP1 in primary platinum drug-resistant cell strain such as lung cancer 95D is obviously superior to that of other sensitive cell strains of lung cancer. The gene is located in human chromosome 11q13.4, wherein the total length of sequence is 1834bp, the open reading frame is 708bp, and 235 amino acids are encoded. The application not only provides new information for tumor drug-resistant mechanism, but also provides new target for the design of anti-tumor drug-resistant drugs.

The invention provides a polypeptide-antibody immune conjugate and a preparation method thereof. The immune conjugate is formed by connecting a polypeptide and an antibody or an antibody FC segment through a covalent bond, wherein the polypeptide is pH-sensitive cell-penetrating peptide. According to the cell-penetrating peptide-antibody immune conjugate, the characteristic of pH response cell penetration of the cell-penetrating peptide is reserved, and the function of causing antibody dependent cell-mediated cytotoxin (ADCC) of the antibody is reserved. An in vitro experiment proves that acid response cell penetration can be achieved by the polypeptide-antibody immune conjugate and the protein of the antibody or the antibody Fc segment is anchored on a cell membrane to induce ADCC. An in vivo experiment proves that the polypeptide-antibody immune conjugate is capable of obviously inhibiting growth of murine melanoma and breast cancer and can be applied to immunotherapy of a clinical solid tumor.

The invention discloses a method for producing an avian encephalomyelitis virus inactivated vaccine. The method comprises the following steps: a. selecting cell lines to serve as cells for preparing the vaccine; b. passing and culturing the cells for preparing the vaccine; c. breeding a virus seed for production; d. producing venom for preparing the vaccine; and e. preparing the vaccine. According to the method disclosed by the invention, continuous cell lines are used as the cells for preparing the vaccine, and sensitive cell lines are screened to reinforce the match of the virus and the cells. The method disclosed by the invention has the advantages of simple and stable production process, easiness in operation, small batch difference and low cost, and the safety and immunogenicity of the produced avian encephalomyelitis virus inactivated vaccine are good.